Similarly, MAGE-C2, expressed in 39% of melanomas and absent in normal tissues, and SLC45A2, a melanocyte lineage antigen highly expressed in UM cell lines but minimally in normal tissues, have also been validated as effective TCR targets. This evidence concerns the gene MAGEC2 and melanoma.